Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascletis Pharma, Inc. ( (HK:1672) ) has shared an update.
Ascletis Pharma has selected ASC37, a next-generation, once‑monthly, subcutaneously administered GLP‑1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for obesity and plans to file an Investigational New Drug application with the U.S. FDA in the second quarter of 2026, with Phase I initiation targeted for the second half of 2026. Discovered and engineered in-house using Ascletis’ AI-enabled and ultra‑long‑acting technologies, ASC37 has shown markedly higher in vitro potency and a roughly 17‑day observed half-life in non-human primate studies—about seven times longer than retatrutide—supporting monthly dosing and potential manufacturing scalability advantages, and is also being positioned for use alone or in combination with the company’s other once‑monthly peptide candidates to address obesity, diabetes and broader cardio‑metabolic diseases, bolstering Ascletis’ ambitions in the competitive metabolic therapeutics market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong that focuses on discovering and developing innovative therapeutics, particularly peptide-based and cardio‑metabolic drugs leveraging its Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform technologies.
Average Trading Volume: 5,355,639
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.27B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.